News & Articles

Forge Therapeutics Wins Powered by CARB-X Research Award of $8.8M to Accelerate Development of its LpxC Antibiotic to Kill the World’s Deadliest ‘Superbugs’ -Award recognizes Forge’s novel chemistry, novel class & novel MOA and highlights urgent need for new antibiotics- -Non-dilutive funding supports Forge’s efficient development strategy-

San Diego, Calif., March 30, 2017 – Forge Therapeutics, Inc., (“Forge”), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, announced today a significant collaboration with CARB-X, ...
Read More

Forge Therapeutics to Present at Biocom Global Life Science Partnering Conference

Forge Therapeutics to Present at Biocom Global Life Science Partnering Conference Company to discuss novel antibiotic program targeting LpxC to kill Gram-negative superbugs   San Diego, Calif., February 28, 2017 ...
Read More

Forge Therapeutics to Present at the 9th Annual Biotech Showcase

San Diego, Calif., January 4, 2017 – Forge Therapeutics, Inc. announced today that it will present at the 9th Annual Biotech Showcase 2017 being held January 9-11, 2017 at the ...
Read More

Forge Therapeutics and Evotec Form Strategic ‘Superbug’ Alliance – Combination of leading innovative chemistry efforts with cutting edge anti-infective drug discovery platform –

San Diego, Calif., December 9, 2016 – Forge Therapeutics, Inc. today announced a strategic alliance with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance its novel Gram-negative ...
Read More

UCSD Start-up Spotlight: Forge Therapeutics

Startup Spotlight: Forge Therapeutics Armed with a novel chemistry platform from the UC San Diego lab of Professor Seth Cohen and Dr. David Puerta, Forge Therapeutics began their transformative work ...
Read More

Forge Therapeutics Adds Superbug Experts Drs Brad Spellberg and Andrew Tomaras to Leading Antibiotic Advisory Team

San Diego, Calif., September 12, 2016 – Forge Therapeutics, Inc. announced the additions of Dr. Brad Spellberg, M.D., Chief Medical Officer of Los Angeles County-University of Southern California (LAC+USC) Medical ...
Read More

Forge Therapeutics Presenting ‘Superbug’ Program at World Anti-Microbial Resistance Congress and Harvard Anti-Infectives Rx Conference

San Diego, Calif., September 7, 2016 – Forge Therapeutics, Inc., announced presentations on its lead program targeting LpxC with novel chemistry to combat Gram-negative ‘superbugs’. Presentations details are as follows: ...
Read More

METAL SMITHING

BioCentury Week of August 22, 2016 EMERGING COMPANY PROFILE BY EMILY CUKIER-MEISNER, SENIOR WRITER Forge Therapeutics Inc. is using a library of metal-binding pharmacophores that avoid known pharmacologic and safety ...
Read More

Forge Therapeutics Scientific Co-Founder Awarded National Chemistry Honor

San Diego, Calif., August 16, 2016 – Forge Therapeutics, Inc. announced today Dr. Seth Cohen, Ph.D., co-founder of Forge Therapeutics and Professor in the Department of Chemistry and Biochemistry at ...
Read More

Forge Therapeutics Receives 1st Federal Funding Award to Advance Superbug Program

World-renowned antibiotic experts form Key Opinion Team to advise Forge San Diego, Calif., July 26, 2016 – Forge Therapeutics, Inc. today announced its 1st funding award from the National Institutes of ...
Read More
Visit Us On Twitter